

33
no
10/16/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY. DOCKET: WALLACH=4A

In re Application of:) Art Unit: 1812
)
David WALLACH et al) Examiner: W. E. Lazar
)
Appln. No.: 08/126,016) Washington, D.C.
)
Filed: September 24, 1993) October 8, 1997
)
For: EXPRESSION OF THE)
RECOMBINANT TUMOR NECROSIS)
FACTOR BINDING PROTEIN ...)

FEE VALUE ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.	
FEE CODE	VALUE FURNISHED

BY HAND-CARRYING

INFORMATION DISCLOSURE STATEMENT [IDS] RECEIVED

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

OCT - 8 1997

MATRIX CUSTOMER
SERVICE CENTER

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR 1.97, as it is filed:

A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

10/10/1997 GDUCKETT 00000024 08126016
01 FC:126 240.00 0P

B. before the mailing date of a first office action on the merits.

[X] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

[] i. Counsel certifies that, upon information and belief, each item of information listed herein was either

[] (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

[] (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[X] ii. A check for the fee set forth in 1.17(p), presently believed to be \$240, is enclosed (check no. 16700).

[X] 2. In accordance with 37 CFR 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached.


[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant

By:


Roger L. Browdy
Reg. No. 25,618

419 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

itt3\wall4a.ids